GERN shares not shaken by departure of CEO |
![]() |
![]() |
By Staff and Wire Reports | |
Wednesday, 09 February 2011 13:37 | |
![]() Alexander E. Barkas, Ph.D., the chairman of the board, who moves to the role of lead independent director said in a prepared statement: The stock has held up nicely considering how abrupt the news was. Some are reporting that the move “reflects the company’s progression into mid-stage clinical development of multiple therapeutic product candidates.” Geron is has candidates in Phase II trials in different cancers and in Phase I for differentiated human embryonic stem cell treatment for spinal cord injury."Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |